RT Journal Article
SR Electronic
T1 Genome-wide analyses of variance in blood cell phenotypes provide new insights into complex trait biology and prediction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.15.24305830
DO 10.1101/2024.04.15.24305830
A1 Xiang, Ruidong
A1 Liu, Yang
A1 Ben-Eghan, Chief
A1 Ritchie, Scott
A1 Lambert, Samuel A.
A1 Xu, Yu
A1 Takeuchi, Fumihiko
A1 Inouye, Michael
YR 2024
UL http://medrxiv.org/content/early/2024/04/16/2024.04.15.24305830.abstract
AB Blood cell phenotypes are routinely tested in healthcare to inform clinical decisions. Genetic variants influencing mean blood cell phenotypes have been used to understand disease aetiology and improve prediction; however, additional information may be captured by genetic effects on observed variance. Here, we mapped variance quantitative trait loci (vQTL), i.e. genetic loci associated with trait variance, for 29 blood cell phenotypes from the UK Biobank (N∼408,111). We discovered 176 independent blood cell vQTLs, of which 147 were not found by additive QTL mapping. vQTLs displayed on average 1.8-fold stronger negative selection than additive QTL, highlighting that selection acts to reduce extreme blood cell phenotypes. Variance polygenic scores (vPGSs) were constructed to stratify individuals in the INTERVAL cohort (N∼40,466), where genetically less variable individuals (low vPGS) had increased conventional PGS accuracy (by ∼19%) than genetically more variable individuals. Genetic prediction of blood cell traits improved by ∼10% on average combining PGS with vPGS. Using Mendelian randomisation and vPGS association analyses, we found that alcohol consumption significantly increased blood cell trait variances highlighting the utility of blood cell vQTLs and vPGSs to provide novel insight into phenotype aetiology as well as improve prediction.Competing Interest StatementM.I. is a trustee of the Public Health Genomics (PHG) Foundation, a member of the Scientific Advisory Board of Open Targets, and has research collaborations with AstraZeneca, Nightingale Health and Pfizer which are unrelated to this study.Funding StatementThe authors are grateful to UK Biobank for access to data to undertake this study (Projects #30418). This work was supported by core funding from the: British Heart Foundation (RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (NIHR203312), Cambridge BHF Centre of Research Excellence (RE/18/1/34212) and BHF Chair Award (CH/12/2/29428) and by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. X.J. was funded by the British Heart Foundation (CH/12/2/29428) and Wellcome Trust (227566/Z/23/Z). S.C.R. was funded by a British Heart Foundation (BHF) Programme Grant (RG/18/13/33946). S.C.R. was also funded by the National Institute for Health and Care Research (NIHR) Cambridge BRC (BRC-1215-20014; NIHR203312) [*]. Y.X. and M.I. were supported by the UK Economic and Social Research Council (ES/T013192/1). M.I. and S.L. were supported by NIH U24 (5U24HG012542-02). M.I. is supported by the Munz Chair of Cardiovascular Prediction and Prevention and the NIHR Cambridge Biomedical Research Centre (NIHR203312) [*]. *The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data described are available through the UK Biobank subject to approval from the UK Biobank access committee. See https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access for further details. INTERVAL study data from this paper are available to bona fide researchers from helpdesk@intervalstudy.org.uk and information, including the data access policy, is available at http://www.donorhealth-btru.nihr.ac.uk/project/bioresource.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes